| Patient # |
Diagnosis |
Dose prescribed |
No. of fractions |
OAR doses [Gy] |
TCP |
| Standard-plan |
Biop-plan |
|
Organs |
Standard-plan |
Biop-plan |
Standard-plan |
Biop-plan |
| 1 |
Primary tumor: Carcinoma of naso-pharynx |
PTV1: nasopharynx + prophylactic dose to first two levels of lymph node change, 21.6 Gy |
bPTV 1: 60.5 Gy, 96% of total target volume (PTV1), 0.57·104 Bq/ml§ |
28 |
Eye, right (max): |
2.8 |
2.8 |
46.3% |
74.0% |
| Eye, left (max): |
2.5 |
2.4 |
| Thyroid (mean): |
0.9 |
1.0 |
| Mandible* (max): |
D33:46.6 D66:34.5 D100: 60.5 |
D33:43.4 D66:37.0 D100: 61.6 |
| |
Secondary tumor: Cervical lymphadenopathy |
PTV2: boost to nasopharynx (PTV2 PTV1), 50.4 Gy |
bPTV 2: 75 Gy, 4% of total target volume, 1.42·104 Bq/ml§ |
|
Spinal cord (max): |
44.6 |
44.1 |
| Parotid, right (mean): |
24.3 |
25.9 |
| Parotid, left (mean): |
24.4 |
25.4 |
| Brainstem (max): |
53.1 |
50.5 |
| 2 |
Epidermoidal carcinoma of the vocal cord, larynx. Moderately differentiated |
PTV1: all of tumor and prophylactic dose to cervical nodules, 45 Gy |
bPTV 1: 63 Gy, 64% of total target volume (PTV1), 1.85·103 Bq/ml§ |
25 |
Eye, right (max): |
1.1 |
1.5 |
14.4% |
67.6% |
| Eye, left (max): |
1.1 |
1.4 |
| Thyroid* (mean): |
27.0 |
32.4 |
| |
. |
PTV2: boost to positive cervical nodules and tumor (PTV2 PTV1), 10 Gy |
bPTV 2: 69.75 Gy, 36% of total target volume, 4.67·103 Bq/ml§ |
Mandible* (max): |
D33:36.8 D66:30.2 D100:52.0 |
D33:51.1 D66:40.0 D100:80.9 |
| Spinal cord (max): |
44.7 |
44.5 |
| Parotid, right (mean): |
23.6 |
23.2 |
| |
|
PTV3: boost to tumor (PTV3 PTV2), 14 Gy |
|
Parotid, left (mean): |
24.1 |
23.4 |
| Brainstem (max): |
45.7 |
51.3 |
| 3 |
Carcinoma of oro-pharynx, oral cavity. Moderately differentiated and positive nodes on right side. Had surgery however dose prescribed is radical. |
PTV1: tumor volume, 54 Gy |
bPTV 1: 77 Gy, 70% of total target volume (PTV1 PTV2 PTV3), 1.96·103 Bq/ml§ |
30 |
Eye, right (max): |
0.8 |
1.0 |
28.3% |
91.2% |
| Eye, left (max): |
0.7 |
0.9 |
| Thyroid* (mean): |
9.7 |
11.1 |
| Mandible* (max): |
D33:37.2 D66:17.6 D100:59.2 |
D33:40.3 D66:21.2 D100:76.6 |
| PTV2: right nodes, 60 Gy |
bPTV 2: 70.5 Gy, 30% of total target volume, 4.61·103 Bq/ml§ |
Spinal cord (max): |
41.9 |
43.0 |
| PTV3: left nodes prophylactic dose, 46 Gy |
|
Parotid, right (mean): |
10.0 |
12.72 |
| Parotid, left (mean): |
6.3 |
8.8 |
| Brainstem (max): |
1.8 |
2.3 |
| 4 |
Glottis carcinoma, larynx. Moderately differentiated with primary tumor on right vocal cord, secondary on left vocal cord. Necrosis in center of tumor. No prophylactic dose to lymph nodes because of high age. |
PTV: 70 Gy |
bPTV 1: 73 Gy, 98% of total target volume (PTV), 0.80·104 Bq/ml§ |
35 |
Eye, right (max): |
0.2 |
0.2 |
75.5% |
83.2% |
| Eye, left (max): |
0.2 |
0.2 |
| Thyroid* (mean): |
25.1 |
27.0 |
| bPTV 2: 78.25 Gy, 2% of total target volume, 5.89·104 Bq/ml§ |
Mandible (max): |
D33:0.9 D66:0.6 D100:21.4 |
D33:1.0 D66:0.6 D100:22.8 |
| Spinal cord (max): |
43.1 |
43.1 |
| Parotid, right (mean): |
0.4 |
0.4 |
| Parotid, left (mean): |
0.5 |
0.5 |
| 5 |
Supraglottis carcinoma, poorly differentiated and bilateral cervical positive |
PTV1: primary tumor and cervical nodes, 50.4 Gy |
bPTV 1: 61.5 Gy, 61% of total target volume (PTV1), 2.51·103 Bq/ml§ |
28 |
Eye, right (max): |
2.0 |
2.2 |
22.2% |
31.7% |
| Eye, left (max): |
2.0 |
2.2 |
| Thyroid*(mean): |
45.4 |
55.8 |
| PTV2: boost to primary tumor (PTV2 PTV1), 16 Gy |
bPTV 2: 65.5 Gy, 39% of total target volume, 5.19·103 Bq/ml§ |
| Mandible * (max): |
D33:48.4 D66:38.5 D100:70.2 |
D33:50.0 D66:35.4 D100:100.0 |
| Spinal cord (max): |
43.5 |
44.9 |
| Parotid, right (mean): |
31.2 |
24.5 |
| Parotid, left* (mean): |
36.6 |
22.9 |
Where Dx: x% of the total volume receives the given dose; VxGy:
Percentage of organ volume that receives the dose limit x; § Mean
FDG uptake in the region; *Organ at risk partly included in target
volume.